Listed

Evolent Health, Inc.: Form 10-Q for the period ended Jun 30, 2023

Filed with the SEC on Aug 3, 2023 and accepted by EDGAR at Aug 2, 2023, 18:14 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2023-04-01 to 2023-06-30$469.1mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2023-01-01 to 2023-06-30$896.8mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2023-04-01 to 2023-06-30$351.9mus-gaap:CostOfRevenue
Cost of revenue6 months2023-01-01 to 2023-06-30$662.4mus-gaap:CostOfRevenue
Selling, general and administrative3 months2023-04-01 to 2023-06-30$90.4mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2023-01-01 to 2023-06-30$180.1mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2023-04-01 to 2023-06-30−$21.6mus-gaap:OperatingIncomeLoss
Operating income6 months2023-01-01 to 2023-06-30−$31.9mus-gaap:OperatingIncomeLoss
Interest expense3 months2023-04-01 to 2023-06-30$14.5mus-gaap:InterestExpense
Interest expense6 months2023-01-01 to 2023-06-30$27.4mus-gaap:InterestExpense
Income tax3 months2023-04-01 to 2023-06-30−$970.0kus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2023-01-01 to 2023-06-30−$69.2mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2023-04-01 to 2023-06-30−$34.3mus-gaap:NetIncomeLoss
Net income6 months2023-01-01 to 2023-06-30−$54.3mus-gaap:NetIncomeLoss
Diluted EPS3 months2023-04-01 to 2023-06-30−$0.37us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2023-01-01 to 2023-06-30−$0.62us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-04-01 to 2023-06-30−$0.37us-gaap:EarningsPerShareBasic
Basic EPS6 months2023-01-01 to 2023-06-30−$0.62us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-04-01 to 2023-06-30111,278,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2023-01-01 to 2023-06-30109,540,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2023-01-01 to 2023-06-30−$7.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2023-06-30$142.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-06-30$576.7mus-gaap:AssetsCurrent
Total assetsAt period end2023-06-30$2.65bnus-gaap:Assets
Current liabilitiesAt period end2023-06-30$540.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-06-30$1.38bnus-gaap:Liabilities
Long-term debtAt period end2023-06-30$633.0mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2023-06-30$1.09bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001628908-23-000121. Last ingested by Listed: Nov 15, 2026, 04:22 ET. Listed shows no prices and gives no investment advice.